- Investing Ideas
- Swedish Pharmaceuticals & Biotech Potentially Undervalued Small Caps
Swedish Pharmaceuticals & Biotech Potentially Undervalued Small Caps
Results
5
Value score of at least 4 focused on companies with a low market cap.
5 companies
Cantargia
Market Cap: SEK 537.0m
A biotechnology company, develops pharmaceuticals for treatment of cancer, inflammatory, and autoimmune diseases.
CANTA
SEK 2.16
7D
1.9%
1Y
102.6%
Sprint Bioscience
Market Cap: SEK 388.3m
A pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden.
SPRINT
SEK 3.68
7D
7.3%
1Y
746.0%
Double Bond Pharmaceutical International
Market Cap: SEK 12.9m
A pharmaceutical company, engages in the development and commercialization of approaches for the treatment of oncological and infectious diseases.
DBP B
SEK 0.12
7D
9.1%
1Y
-72.7%
Guard Therapeutics International
Market Cap: SEK 32.1m
A clinical-stage biotechnology company, identifies and develops medicines to treat kidney diseases in Sweden.
GUARD
SEK 1.59
7D
13.6%
1Y
-90.9%
Subgen AI
Market Cap: SEK 71.1m
Develops artificial intelligence-based models and applications to control data for government and businesses.
SUBGEN
SEK 0.07
7D
-27.3%
1Y
n/a